| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ethyl rosmarinate inhibits the activity of tyrosinase, α-glucosidase, and matrix metalloproteinase-1 (MMP-1). It potently inhibits LPS-induced production of nitric oxide and prostaglandin E2 in alveolar macrophages. It induces relaxation in aortic rings via an endothelium-independent pathway.
|
|---|---|
| ln Vitro |
In vitro, Ethyl rosmarinate has antioxidative activity. It inhibits lung inflammation. It potently inhibits LPS-induced production of nitric oxide and prostaglandin E2 in alveolar macrophages. It induces relaxation in aortic rings via an endothelium-independent pathway. It inhibits tyrosinase, α-glucosidase, and MMP-1 activity.
|
| ln Vivo |
In vivo, Ethyl rosmarinate inhibits lung inflammation. Its anti-inflammatory and antioxidative properties suggest potential for treating inflammatory diseases. However, detailed in vivo studies are limited. The compound's ability to induce vasorelaxation suggests potential cardiovascular effects. Further animal studies are needed.
|
| Enzyme Assay |
Cell-free assays for Ethyl rosmarinate: tyrosinase inhibition is measured using L-DOPA as substrate, monitoring absorbance at 475 nm. α-Glucosidase inhibition is assessed using p-nitrophenyl-α-D-glucopyranoside, measuring absorbance at 405 nm. MMP-1 inhibition is measured using fluorogenic substrates. Antioxidant activity is evaluated using DPPH and ABTS radical scavenging assays.
|
| Cell Assay |
Cellular assays for Ethyl rosmarinate: alveolar macrophages are cultured and treated with Ethyl rosmarinate at concentrations of 0.1-100 µM for 1-24 hours, then stimulated with LPS. Nitric oxide production is measured by Griess reaction. Prostaglandin E2 levels are measured by ELISA. Cell viability is assessed by MTT assay. Aortic ring relaxation assays are performed using isolated aortic rings.
|
| Animal Protocol |
In vivo animal studies for Ethyl rosmarinate: animal models of lung inflammation would be used. Animals are administered Ethyl rosmarinate orally or intraperitoneally at doses of 10-50 mg/kg. Inflammatory markers, cytokine levels, and histological analysis of lung tissue are assessed. Vasorelaxation effects are studied in cardiovascular models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ethyl rosmarinate are limited. As a phenolic ester with molecular weight 388.37, it may have moderate oral bioavailability. It is likely metabolized by esterases to release rosmarinic acid. Tissue distribution and elimination pathways require further investigation. The compound should be stored desiccated, protected from light, at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity of Ethyl rosmarinate: comprehensive toxicity data are limited. As a phenolic compound from medicinal plants, it is generally considered safe at moderate doses. However, high doses may cause irritation or sensitization. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Ethyl rosmarinic acid has been reported to have been found in Pogostemon cablin, Mallotus philippinensis, and other organisms with available data.
Ethyl rosmarinate is a research compound with potential applications in anti-inflammatory, antioxidative, and skin-lightening research. It is available as a reference standard for pharmacological studies. Its mechanism involves inhibition of tyrosinase, α-glucosidase, and MMP-1. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C20H20O8
|
|---|---|
| Molecular Weight |
388.37
|
| Exact Mass |
388.115
|
| CAS # |
174591-47-0
|
| PubChem CID |
44437692
|
| Appearance |
White to off-white solid
|
| Density |
1.413±0.06 g/cm3(Predicted)
|
| Boiling Point |
658.7±55.0 °C(Predicted)
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
28
|
| Complexity |
548
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@@H](OC(/C=C/C1=CC(O)=C(O)C=C1)=O)C(OCC)=O)C1=CC(O)=C(O)C=C1
|
| InChi Key |
ROJRNQOAUDCMES-KRZKXXONSA-N
|
| InChi Code |
InChI=1S/C20H20O8/c1-2-27-20(26)18(11-13-4-7-15(22)17(24)10-13)28-19(25)8-5-12-3-6-14(21)16(23)9-12/h3-10,18,21-24H,2,11H2,1H3/b8-5+/t18-/m1/s1
|
| Chemical Name |
ethyl (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxypropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5749 mL | 12.8743 mL | 25.7486 mL | |
| 5 mM | 0.5150 mL | 2.5749 mL | 5.1497 mL | |
| 10 mM | 0.2575 mL | 1.2874 mL | 2.5749 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
